BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Langan RC, Ripley RT, Davis JL, Prieto PA, Datrice N, Steinberg SM, Bratslavsky G, Rudloff U, Kammula US, Stojadinovic A. Liver directed therapy for renal cell carcinoma. J Cancer. 2012;3:184-190. [PMID: 22558019 DOI: 10.7150/jca.4456] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Pinotti E, Montuori M, Giani A, Uggeri F, Garancini M, Gianotti L, Romano F. Surgical treatment of liver metastases from kidney cancer: a systematic review. ANZ J Surg. 2019;89:32-37. [PMID: 30685878 DOI: 10.1111/ans.15000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Hamada S, Ito K, Kuroda K, Sato A, Asakuma J, Horiguchi A, Seguchi K, Asano T. Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol 2015;3:63-8. [PMID: 25469271 DOI: 10.3892/mco.2014.432] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
3 Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE. The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg. 2014;399:989-1000. [PMID: 25148767 DOI: 10.1007/s00423-014-1241-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
4 Kim SH, Kim JK, Park EY, Joo J, Lee KH, Seo HK, Joung JY, Chung J. Liver metastasis and Heng risk are prognostic factors in patients with non-nephrectomized synchronous metastatic renal cell carcinoma treated with systemic therapy. PLoS One 2019;14:e0211105. [PMID: 30785902 DOI: 10.1371/journal.pone.0211105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Bruns F, Christiansen H. Is there always a need for invasive treatment of limited liver metastases in renal cell cancer or other solid tumors? World J Urol 2015;33:443-4. [PMID: 24880999 DOI: 10.1007/s00345-014-1331-4] [Reference Citation Analysis]
6 Kim SH, Park WS, Park B, Pak S, Chung J. A Retrospective Analysis of the Impact of Metastasectomy on Prognostic Survival According to Metastatic Organs in Patients With Metastatic Renal Cell Carcinoma. Front Oncol. 2019;9:413. [PMID: 31179242 DOI: 10.3389/fonc.2019.00413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Neri F, Ercolani G, Di Gioia P, Del Gaudio M, Pinna AD. Liver metastases from non-gastrointestinal non-neuroendocrine tumours: review of the literature. Updates Surg 2015;67:223-33. [PMID: 26341625 DOI: 10.1007/s13304-015-0315-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
8 Pikoulis E, Margonis GA, Antoniou E. Surgical Management of Renal Cell Cancer Liver Metastases. Scand J Surg 2016;105:263-8. [PMID: 26929295 DOI: 10.1177/1457496916630644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Schneider G, Probst T, Kirchin MA, Stroeder J, Fries P, Buecker A. Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions. Radiol Med 2015;120:1100-11. [PMID: 26088468 DOI: 10.1007/s11547-015-0548-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol 2014;31:978. [PMID: 24793747 DOI: 10.1007/s12032-014-0978-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
11 Chatzizacharias NA, Rosich-Medina A, Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK, Jah A. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol 2017; 9(2): 70-77 [PMID: 28255428 DOI: 10.4251/wjgo.v9.i2.70] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
12 Kim JK, Kim SH, Song MK, Joo J, Seo SI, Kwak C, Jeong CW, Song C, Hwang EC, Seo IY, Lee H, Hong SH, Park JY, Chung J. Survival and clinical prognostic factors in metastatic non-clear cell renal cell carcinoma treated with targeted therapy: A multi-institutional, retrospective study using the Korean metastatic renal cell carcinoma registry. Cancer Med 2019;8:3401-10. [PMID: 31070307 DOI: 10.1002/cam4.2222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
13 Sofocleous CT, Sideras P, Petre EN. “How we do it” - a practical approach to hepatic metastases ablation techniques. Tech Vasc Interv Radiol. 2013;16:219-229. [PMID: 24238377 DOI: 10.1053/j.tvir.2013.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
14 Hau HM, Thalmann F, Lübbert C, Morgul MH, Schmelzle M, Atanasov G, Benzing C, Lange U, Ascherl R, Ganzer R, Uhlmann D, Tautenhahn HM, Wiltberger G, Bartels M. The value of hepatic resection in metastasic renal cancer in the Era of Tyrosinkinase Inhibitor Therapy. BMC Surg 2016;16:49. [PMID: 27444582 DOI: 10.1186/s12893-016-0163-0] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]